Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2010 Scrip 100 - David Brennan juggling pharma and PhRMA

This article was originally published in Scrip

Executive Summary

It was never going to be a quiet year for David Brennan. A slowing pipeline, neutral ratings from analysts and a recession were among the challenges that AstraZeneca's CEO addressed in 2009. Now he's fighting the industry's corner as the US market braces itself for healthcare reform. He tells Christopher Spillane how pharma is getting reform on its own terms as the industry contracts.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts